Earnings summaries and quarterly performance for Caris Life Sciences.
Research analysts covering Caris Life Sciences.
Recent press releases and 8-K filings for CAI.
Caris Life Sciences Reports Strong 2025 Financials and Outlines 2026 Growth Initiatives
CAI
Earnings
Product Launch
New Projects/Investments
- Caris Life Sciences ended 2025 with over $800 million in cash and a strong P&L generating significant cash flows and profitability, driven by ASP pricing.
- The company reported $281 million in revenue for 2025, which included $135 million in true-ups (with $102 million related to 2025 cases). The Q4 tissue base ASP was $3,800, and blood ASP stepped up to $2,500.
- In 2025, Caris completed 199,300 individual genomic profiles, representing a 22% case volume increase for the year, and surpassed 1 million individual genomic profiles in its data set.
- Key product pipeline developments include the imminent launch of Caris ChromaSEQ (whole genome for hematological malignancies) pending MolDX review, the MyClarity AI-driven assay for breast cancer recurrence, and a new whole genome-based tissue-informed MRD assay.
- Caris closed a Caris Discovery project with Genentech with a $20 million upfront milestone payment and a total contract value over $1 billion, which is expected to contribute to 2026 revenue. The company plans to expand its commercial organization and pharma team by 20-25% headcount in 2026 to drive growth.
3 days ago
Caris Life Sciences Reports Strong Q4 2025 Revenue Growth and Pipeline Advancements
CAI
Revenue Acceleration/Inflection
Product Launch
New Projects/Investments
- Caris Life Sciences reported $281 million in Q4 2025 revenues, reflecting 116% year-over-year growth, and ended 2025 with over $800 million in cash.
- The company processed 199,300 genomic profiles in 2025, a 22% year-over-year increase, bringing its total data set to over 1 million individual genomic profiles.
- Key pipeline updates include expected AchieveOne study results by the end of Q1 2026 for its Multi-Cancer Early Detection (MSED) test, which will launch commercially with EverlyWell at a $3,500 price point.
- For 2026, Caris plans significant investments, including a 20%-25% increase in commercial sales headcount and a substantial expansion of its pharma team to drive further growth.
- A Caris Discovery project with Genentech was finalized in late Q4 2025, featuring a $20 million upfront milestone payment and a total contract value exceeding $1 billion.
3 days ago
Caris Life Sciences Reports Strong Q4 2025 Results and Outlines 2026 Growth Initiatives
CAI
Revenue Acceleration/Inflection
Product Launch
New Projects/Investments
- Caris Life Sciences reported Q4 2025 revenues of $281 million, a 116% year-over-year increase, and ended the year with over $800 million in cash.
- The company achieved 20% year-over-year case volume growth in Q4 2025, reaching 52,700 cases, and a 22% growth for the full year 2025 with 199,300 cases. The Q4 tissue base Average Selling Price (ASP) was $3,800.
- Caris is preparing for the commercial launch of its Multi-Cancer Early Detection (MCED) test with Everlywell at a $3,500 price point, following the AchieveOne study readout towards the end of Q1 2026.
- Significant investments are planned for 2026, including a 20-25% increase in commercial headcount and expansion of the pharma team to drive further growth.
3 days ago
Caris Life Sciences Announces Preliminary Q4 and Full Year 2025 Results
CAI
Earnings
Revenue Acceleration/Inflection
- Caris Life Sciences announced preliminary, unaudited total revenue of approximately $281 million for Q4 2025, an increase of approximately 116% compared to the same period in 2024.
- For the full year 2025, preliminary total revenue reached approximately $800 million, representing an increase of approximately 94% over the full year 2024.
- The company completed approximately 52,700 clinical therapy selection cases in Q4 2025 and approximately 199,300 cases for the full year 2025, reflecting increases of approximately 20% and 22% respectively.
- Preliminary cash, cash equivalents, restricted cash, and marketable securities totaled approximately $802 million as of December 31, 2025, a net increase of approximately $43 million from September 30, 2025.
4 days ago
Caris Life Sciences Announces Collaboration with Genentech
CAI
New Projects/Investments
- Caris Life Sciences' therapeutic research arm, Caris Discovery, has entered into a multi-year collaboration and license agreement with Genentech to identify and validate novel oncology targets in solid tumor tissue.
- Caris is eligible to receive $25 million in upfront and near-term payments.
- Additionally, Caris is eligible for up to $1.1 billion in potential research, development, commercial, and net sales milestone payments, as well as potential tiered royalties on net sales of collaboration therapies.
- The collaboration aims to combine Caris' unparalleled multimodal data and tissue-based discovery engine with Genentech's expertise to enable the development of first-in-class medicines for cancer patients.
Dec 16, 2025, 1:30 PM
Caris Life Sciences Reports Record Q3 2025 Revenue and Raises Full-Year Guidance
CAI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Caris Life Sciences reported record Q3 2025 total revenues of $216.8 million, an increase of 113% year-over-year, driven by clinical profiling services revenue of $207.6 million, up 121% year-over-year.
- The company achieved significant profitability, with positive adjusted EBITDA of $51.2 million, net income of $24.3 million, and positive free cash flow of $55.3 million. Gross margins improved to 68%, up from 43.7% in Q3 2024.
- Clinical case volumes grew 18.2% year-over-year to slightly less than 51,000 profiles, and the average selling price (ASP) per profile increased 87% year-over-year to $4,089, including a $37.9 million revenue true-up.
- Caris raised its full-year 2025 total revenue guidance to $720 million-$730 million, representing a 75%-77% increase over 2024, and increased its clinical therapy selection volume growth expectation to 21%-22%.
- The Achieve One early detection study is complete with 3,000 subjects, and the Achieve Two study is well underway with over 15,600 patients enrolled, with Achieve One results expected in the first half of next year.
Nov 5, 2025, 9:30 PM
CAI Announces Strong Q3 2025 Financial Results and Updated Guidance
CAI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- CAI reported Total Revenue of $216.8 million for Q3 2025, marking a 113% increase year-over-year.
- The company achieved Positive Adjusted EBITDA of $51.2 million and GAAP Net Income of $24.3 million in Q3 2025.
- Gross margin expanded to 68%, an improvement of approximately 2,432 basis points year-over-year.
- Clinical volume increased by 18% to 50,763 clinical cases, and Clinical ASP improved by 87% to $4,089 in Q3 2025.
- CAI updated its full-year 2025 Total Revenue guidance to $720 million – $730 million, projecting 75-77% year-over-year growth.
Nov 5, 2025, 9:30 PM
Caris Life Sciences Reports Strong Q3 2025 Results and Raises Full-Year Revenue Guidance
CAI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Caris Life Sciences reported total revenue of $216.8 million for the third quarter of 2025, an increase of 113.4% over the corresponding prior year period.
- The company achieved net income of $24.3 million and positive Adjusted EBITDA of $51.2 million for Q3 2025.
- Caris Life Sciences reported positive net cash flow from operating activities of $62.4 million for the quarter ended September 30, 2025.
- The company raised its full-year 2025 revenue guidance to a range of $720 to $730 million, representing year-over-year growth of 75% to 77%.
Nov 5, 2025, 9:17 PM
Caris Life Sciences Reports Strong Q3 2025 Results and Raises Full-Year Guidance
CAI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Caris Life Sciences reported Q3 2025 total revenue of $216.8 million, an increase of 113.4% over the corresponding prior year period.
- The company achieved net income of $24.3 million and positive Adjusted EBITDA of $51.2 million for Q3 2025.
- Clinical therapy selection cases grew 18.2% to 50,763, contributing to a gross margin of 68.0%.
- Caris Life Sciences generated positive net cash flow from operating activities of $62.4 million and positive free cash flow of $55.3 million in Q3 2025.
- The company raised its full-year 2025 revenue guidance to a range of $720 million to $730 million, representing 75% to 77% year-over-year growth.
Nov 5, 2025, 9:05 PM
Quarterly earnings call transcripts for Caris Life Sciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more